Targeting DHFR in parasitic protozoa

Drug Discovery Today

Volumn 10, Issue 2, 2005, Pages 121-128

  Anderson, Amy C ^a  

^a Dartmouth College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 [5' [(5 CARBOXYPENTYL) 2' METHOXY]BENZYL]PYRIMIDINE; 2,4 DIAMINO 5 METHYL 6 (2',5' DIMETHOXYPHENYLTHIO)PYRROLO[2,3 D]PYRIMIDINE; 2,4 DIAMINO 6 [2' O (3 CARBOXYPROPYL)OXYDIBENZ[B,F]AZEPIN 5 YL]METHYLPTERIDINE; 4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLORCYCLOGUANIL; CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; CLINDAMYCIN; COTRIMOXAZOLE; CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROPTEROATE SYNTHASE; FANSIDAR; FOLIC ACID ANTAGONIST; FOLINIC ACID; METHOTREXATE; N [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] N' ISOPROPYLIMIDOCARBONIMIDIC DIAMIDE; PIRITREXIM; PROGUANIL; PTERIDINE DERIVATIVE; PYRIMETHAMINE; PYRIMIDINE DERIVATIVE; SULFADIAZINE; SULFADOXINE; THYMIDYLATE SYNTHASE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SYNTHESIS; APICOMPLEXA; BINDING AFFINITY; CLINICAL TRIAL; CRYPTOSPORIDIOSIS; DRUG ABSORPTION; DRUG DESIGN; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; FOLIC ACID DEFICIENCY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; MALARIA; MOLECULAR MODEL; NONHUMAN; NUCLEIC ACID SYNTHESIS; PLASMODIUM; PNEUMOCYSTIS PNEUMONIA; REVIEW; TOXOPLASMOSIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS; FOLIC ACID ANTAGONISTS; HUMANS; PROTOZOA; PROTOZOAN INFECTIONS; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 13844298790     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03308-2     Document Type: Review

References (52)

1. Frevert U. Sneaking in through the back entrance: the biology of malaria liver stages. Trends Parasitol. 20:2004;417-424
2. Tenter A., et al. Toxoplasma gondii: from animals to humans. Int. J. Parasitol. 30:2000;1217-1258
3. Hayde M., et al. Clinical picture: neonatal signs and symptoms. Ambroise-Thomas P., Petersen E. Congenital toxoplasmosis: scientific background, clinical management and control. 2000;153-164 Springer-Verlag
4. Fayer R., et al. Epidemiology of Cryptosporidium: transmission, detection and identification. Int. J. Parasitol. 30:2000;1305-1322
5. Guerrant R. Cryptosporidiosis: an emerging, highly infectious threat. Emerg. Infect. Dis. 3:1997;51-57
6. Neill M., et al. Cryptosporidiosis: an unrecognized cause of diarrhea in elderly hospitalized patients. Clin. Infect. Dis. 22:1996;168-170
7. Cordell R., et al. Cryptosporidiosis in child-care settings: a review of the literature and recommendations for prevention and control. Pediatr. Infect. Dis. J. 13:1994;310-317
8. MacKenzie W., et al. A massive outbreak in Milwaukee of Cryptosporidium infection transmitted through the public water supply. N. Engl. J. Med. 331:1994;161-167
9. Fleming G., et al. Antifolates: the next generation. Semin. Oncol. 19:1992;707-719
10. Bertino J. Karnofsky Memorial Lecture: Ode to methotrexate. J. Clin. Oncol. 11:1993;5-14
11. Salter A. Trimethoprim-sulfamethoxazole: An assessment of more than 12 years of use. Rev. Infect. Dis. 4:1982;196-236
12. Roth B., et al. 2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 7. Analysis of the effect of 3,5-dialkyl substituent size and shape on binding to four different dihydrofolate reductase enzymes. J. Med. Chem. 30:1987;348-356
13. Plowe C., et al. Sustained efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first-line treatment: five-year prospective study. BMJ. 328:2004;545-548
14. Watkins W., et al. The efficacy of antifolate antimalarial combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol. Today. 13:1997;459-464
15. Striepen B., et al. Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 101:2004;3154-3159
16. Abrahamsen M., et al. Complete genome sequence of the Apicomplexan, Cryptosporidium parvum. Science. 304:2004;441-445
17. Yuvaniyama J., et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol. 10:2003;357-365
18. Armstrong C., et al. Cyclization and N-dealkylation of chloro-guanide by rabbit and rat hepatic microsomes. Tox. App. Pharm. 29:1974;90
19. Wang P., et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol. Biochem. Parasitol. 89:1997;161-177
20. Looareesuwan S., et al. Drug resistant malaria, with special reference to Thailand. Southeast Asian J. Trop. Med. Public Health. 23:1992;621-634
21. White N. Assessment of the pharmocodynamic properties of antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41:1997;1413-1422
22. Sibley C., et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 17:2001;582-588
23. Sirawaraporn W., et al. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl. Acad. Sci. U. S. A. 94:1997;1124-1129
24. Yuthavong Y., et al. Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum. J. Med. Chem. 43:2000;2738-2744
25. Cowman A. Mechanisms of drug resistance in malaria. Aust. N. Z. J. Med. 25:1995;837-844
26. Winstanley P., et al. In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob. Agents Chemother. 39:1995;948-952
27. Nzila A., et al. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob. Agents Chemother. 42:1998;164-169
28. Alloueche A., et al. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet. 363:2004;1843-1848
29. Hekmat-Nejad M., et al. Plasmodium falciparum: Kinetic interactions of WR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase. Exp. Parasitol. 87:1997;222-228
30. Hankins E., et al. Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210. Mol. Biochem. Paras. 117:2001;91-102
31. Canfield C., et al. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am. J. Trop. Med. Hyg. 49:1993;121-126
32. Rieckmann K., et al. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. Trans. R. Soc. Trop. Med. Hyg. 90:1996;568-571
33. Chio L-C., et al. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 37:1993;1914-1923
34. Klepser M., et al. Drug treatment of HIV-related opportunistic infections. Drugs. 53:1997;40-73
35. Aspinall T., et al. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J. Infect. Dis. 185:2002;1637-1643
36. Donald R., et al. Stable molecular transformation of Toxoplasma gondii: A selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria. Proc. Natl. Acad. Sci. U. S. A. 90:1993;11703-11707
37. Nelson R., et al. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations. Antimicrob. Agents Chemother. 45:2001;3293-3303
38. Vasquez J., et al. Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum. Mol. Biochem. Parasitol. 79:1996;153-165
39. O'Neil R., et al. Phylogenetic classification of protozoa based on the structure of the linker domain in the bifunctional enzyme, dihydrofolate reductase-thymidylate synthase. J. Biol. Chem. 278:2003;52980-52987
40. Knighton D., et al. Structure of and kinetic channeling in bifunctional dihydrofolate reductase-thymidylate synthase. Nat. Struct. Biol. 1:1994;186-194
41. Cody V., et al. Ligand-induced conformational changes in the crystal structures of Pneumocystis carinii dihydrofolate reductase complexes with folate and NADP+. Biochemistry. 38:1999;4303-4312
42. Cody V., et al. Crystal structure determination at 2.3 Å of recombinant human dihydrofolate reductase ternary complex with NADPH and methotrexate-γ-tetrazole. Anticancer Drug Des. 7:1992;483-491
43. Champness J., et al. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 Å resolution. Structure. 2:1994;915-924
44. Li R., et al. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. Mol. Biol. 295:2000;307-323
45. Oefner C., et al. Crystal structure of human dihydrofolate reductase complexed with folate. Eur. J. Biochem. 174:1988;377-385
46. Warhurst D. Antimalarial drug discovery: development of inhibitors of dihydrofolate reductase active in drug resistance. Drug Discov. Today. 3:1998;538-546
47. McKie J., et al. Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. J. Med. Chem. 41:1998;1367-1370
48. Kamchonwongpaisan S., et al. Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. J. Med. Chem. 47:2004;673-680
49. Rosowsky A., et al. New 2,4-Diamino-5-(2′,5′-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity. J. Med. Chem. 47:2004;1475-1486
50. Rosowsky A., et al. Further studies on 2,4-diamino-5-(2′,5′- disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. J. Med. Chem. 46:2003;1726-1736
51. Gangjee A., et al. Design, synthesis, and biological evaluation of 2,4-Diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. J. Med. Chem. 47:2004;3689-3692
52. Rosowsky A., et al. Synthesis of 2,4-diamino-6-[2′-O-(ω- carboxyalkyl)oxydibenz[b,f]azepin-5-yl]-methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase. J. Med. Chem. 47:2004;2475-2485